Working… Menu
Trial record 1 of 1 for:    NCT00673829
Previous Study | Return to List | Next Study

Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00673829
Recruitment Status : Suspended (Funding)
First Posted : May 7, 2008
Last Update Posted : June 17, 2016
Information provided by (Responsible Party):
Roger Williams Medical Center

Brief Summary:
The purpose of this study is to collect data on the safety and effectiveness of 2nd generation designer T cells in patients with breast cancer. Designer T cells are prepared by collecting white blood cells from the participant, and then modifying these cells in the laboratory so that they recognize the tumor antigen (CEA). These modified cells are then given back to the participant so that they can attack and kill tumor cells.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: Gene Modified T Cells Biological: Gene Modified T Cells and Interleukin 2 Phase 1

Detailed Description:

T cells can penetrate virtually every biologic space and have the power to dispose of normal or malignant cells as seen in viral and autoimmune diseases and in the rare spontaneous remissions of cancer. However, T cells are easily tolerized to self or tumor antigens and "immune surveillance" has manifestly failed in every cancer that is clinically apparent. It is the goal of this study to supply the specificities and affinities to patient T cells without regard for their "endogenous" T cell receptor repertoire, directed by antibody-defined recognition to kill malignant cells based on their expression of antigen. We will achieve this by preparing chimeric IgCD28TCR genes in mammalian expression vectors to yield "designer T cells" from normal patient cells. Prior studies in model systems demonstrated that recombinant IgCD28TCR could direct modified T cells to respond to antigen targets with IL2 secretion, cellular proliferation, and cytotoxicity, the hallmarks of an effective, self-sustaining immune response.

It therefore becomes of paramount interest to extend these studies to a human system of widespread clinical relevance to explore the clinical potential of this new technology. The target antigen for these studies is carcinoembryonic antigen (CEA), which is prominently expressed on tumors of the stomach, colon and rectum, breast, pancreas and other sites.

For the Phase Ia component, patients receive a single dose of gene-modified autologous T cells on this dose-escalation trial. Doses are 10^9 and 10^10 modified T cells. Patients are monitored for safety and response. Patients are on-study for one month after dosing.

For the Phase Ib component, patients receive a fixed dose of gene-modified T cells (10^11 cells), randomized to receive T cell growth factor interleukin 2 (+IL2) [Experimental] or not (-IL2) [Control]. The IL2 is administered outpatient by continuous infusion for a two-week period. On Day +2 and Day +10, the patient's tumor is biopsied to assess the designer T cell presence in the tumor as a means of judging the benefit of added IL2. Patients will also be followed for tumor response.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Study Start Date : May 2008
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Phase Ia Biological: Gene Modified T Cells
Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
Other Names:
  • Designer T-Cells
  • CEA

Experimental: Phase Ib: Control Biological: Gene Modified T Cells and Interleukin 2
One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
Other Names:
  • Designer T-Cells
  • CEA

Primary Outcome Measures :
  1. Phase Ia:Determine the safety of using modified T-cells by documenting the type and severity of any side effects and establishing the maximum tolerated dose (MTD). [ Time Frame: 1 Month ]
  2. Phase Ib: Determine optimal biologic dose (OBD) in terms of value of added interleukin 2. [ Time Frame: 1 Month ]

Secondary Outcome Measures :
  1. Tumor Response [ Time Frame: 1 Month ]
  2. Pharmacokinetic [ Time Frame: 1 month ]
  3. Pharmacodynamic [ Time Frame: 1 Month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have cancer of the breast
  • Must have metastatic or unresectable locally advanced disease
  • Tumor must express CEA by tumor staining or by elevated serum CEA (>10 ng/ml)
  • Must have measurable disease radiologically or by physical exam
  • Must have failed potentially curative standard therapy
  • Must be 18 years of age or older
  • Good performance status (PS 0-1)

Exclusion Criteria:

  • Requiring systemic steroids
  • Serious medical conditions
  • Concurrent malignancies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00673829

Layout table for location information
United States, Massachusetts
Tufts University Medical Center
Boston, Massachusetts, United States, 02115
United States, Rhode Island
Roger Williams Medical Center
Providence, Rhode Island, United States, 02908
Sponsors and Collaborators
Roger Williams Medical Center
Layout table for investigator information
Principal Investigator: Richard P Junghans, PhD, MD Roger Williams Medical Center
Layout table for additonal information
Responsible Party: Roger Williams Medical Center Identifier: NCT00673829    
Other Study ID Numbers: 300-04
First Posted: May 7, 2008    Key Record Dates
Last Update Posted: June 17, 2016
Last Verified: June 2016
Keywords provided by Roger Williams Medical Center:
Breast Cancer
T cells
Gene Transfer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs